Share this article and save a life!
34 years of newborn protection, gone with one committee vote.
The CDC’s Advisory Committee on Immunization Practices (ACIP) just voted to end universal hepatitis B vaccination at birth, reversing a policy that’s been in place since 1991.
Instead of vaccinating all newborns, they now recommend birth doses only for babies whose mothers test positive for hepatitis B or have unknown status.
For all other infants? Start at 2 months, with “shared decision-making.”
🚨 The backlash has been swift and severe.
The American Academy of Pediatrics immediately condemned the decision. Major liver disease societies called it dangerous. Leading pediatricians are publicly stating they’ll continue vaccinating all newborns regardless of the new guidance.
Why this matters for healthcare leaders:
This creates an operational nightmare for birthing hospitals. You now need workflows to confirm every mother’s hepatitis B status at delivery, implement shared decision-making protocols for negative mothers, and manage insurance coverage questions when providers go against ACIP guidance.
The equity implications are staggering.
Communities with higher hepatitis B prevalence, inconsistent prenatal care, or limited healthcare access will bear the brunt of this change. We’re essentially creating a two-tier system where some babies get protection and others don’t, based on their mother’s testing status and ability to navigate complex medical decisions hours after giving birth.
Here’s what makes this unprecedented:
I can’t remember another time when major medical societies have so uniformly rejected an ACIP recommendation and pledged to continue contrary practices. This isn’t just disagreement, it’s open defiance from the pediatric community.
For imaging centers and FQHCs serving diverse populations, this signals potential increases in chronic hepatitis B cases that could have been prevented. More liver disease. More healthcare costs. More preventable suffering.
The real question:
If the experts who actually care for children are rejecting this guidance, why was it changed? And what happens when official policy diverges so dramatically from clinical practice?
We’re watching a public health policy crisis unfold in real time.
♻️ Repost if universal newborn protection shouldn’t be negotiable.
👉 Follow me, Jonathan Govette, for real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
